Search

Your search keyword '"Mao, Ying"' showing total 2,315 results
Start Over Author "Mao, Ying" Publication Type Academic Journals
2,315 results on '"Mao, Ying"'

7. Neural control of lexical tone production in human laryngeal motor cortex.

Author

Lu, Junfeng, Li, Yuanning, Zhao, Zehao, Liu, Yan, Zhu, Yanming, Mao, Ying, Wu, Jinsong, and Chang, Edward

Subjects
Humans, Motor Cortex, Speech Perception, Pitch Perception, Language, Larynx
Abstract

In tonal languages, which are spoken by nearly one-third of the worlds population, speakers precisely control the tension of vocal folds in the larynx to modulate pitch in order to distinguish words with completely different meanings. The specific pitch trajectories for a given tonal language are called lexical tones. Here, we used high-density direct cortical recordings to determine the neural basis of lexical tone production in native Mandarin-speaking participants. We found that instead of a tone category-selective coding, local populations in the bilateral laryngeal motor cortex (LMC) encode articulatory kinematic information to generate the pitch dynamics of lexical tones. Using a computational model of tone production, we discovered two distinct patterns of population activity in LMC commanding pitch rising and lowering. Finally, we showed that direct electrocortical stimulation of different local populations in LMC evoked pitch rising and lowering during tone production, respectively. Together, these results reveal the neural basis of vocal pitch control of lexical tones in tonal languages.

Published
2023

9. Integrative taxonomy reveals unanticipated hidden diversity in the monotypic goosefish genus Lophiomus (Teleostei, Lophiidae), with description of three new species and resurrection of Chirolophius laticeps Ogilby, 1910

Author

Hsuan-Pu Chen, Mao-Ying Lee, and Wei-Jen Chen

Subjects
biodiversity, Indo-West Pacific, anglerfish, multigene phylogeny, Tropical Deep-Sea Benthos, Zoology, QL1-991, Botany, QK1-989
Abstract

Thought to be monotypic for decades, the only species in the goosefish genus Lophiomus Gill, Lm. setigerus (Vahl), shows a wide range of morphological variation and is distributed widely in the Indo-West Pacific (IWP). In this study, datasets for two mitochondrial and two nuclear genes sequences obtained from samples of Lophiomus collected in different localities across the IWP were constructed and analyzed to explore the phylogeny and species diversity within the genus. Our integrated approach with multiline evidence unveiled an unanticipated richness of at least six delimited species of Lophiomus. Herein, based on materials already available from museums and new specimens obtained primarily through the Tropical Deep-Sea Benthos program surveying IWP benthic fauna, we formally describe three new species: Lm. immaculioralis sp. nov., Lm. nigriventris sp. nov., and Lm. carusoi sp. nov. Also, we resurrect Lm. laticeps stat. rev. from synonyms of Lm. setigerus. These species can be diagnosed by genetics, body coloration, patterns on the floor of the mouth, peritoneum pigmentation, morphometric measurements, and meristic counts of cranial spines, dorsal-fin spines, and pectoral-fin and pelvic-fin rays from each other and from Lm. setigerus. The species Lm. setigerus, as well as the genus Lophiomus, are re-described accordingly based on the new results. Amended identification keys to the four extant lophiid genera and to species of Lophiomus are also provided.

Published
2024
Full Text
View/download PDF

19. Author Correction: Identification of recurrent USP48 and BRAF mutations in Cushing’s disease

Author

Chen, Jianhua, Jian, Xuemin, Deng, Siyu, Ma, Zengyi, Shou, Xuefei, Shen, Yue, Zhang, Qilin, Song, Zhijian, Li, Zhiqiang, Peng, Hong, Peng, Cheng, Chen, Min, Luo, Cheng, Zhao, Dan, Ye, Zhao, Shen, Ming, Zhang, Yichao, Zhou, Juan, Fahira, Aamir, Wang, Yongfei, Li, Shiqi, Zhang, Zhaoyun, Ye, Hongying, Li, Yiming, Shen, Jiawei, Chen, Hong, Tang, Feng, Yao, Zhenwei, Shi, Zhifeng, Chen, Chunjui, Xie, Lu, Wang, Ye, Fu, Chaowei, Mao, Ying, Zhou, Liangfu, Gao, Daming, Yan, Hai, Zhao, Yao, Huang, Chuanxin, and Shi, Yongyong

Published
2023
Full Text
View/download PDF

21. Retraction Note: SARI inhibits angiogenesis and tumour growth of human colon cancer through directly targeting ceruloplasmin

Author

Dai, Lei, Cui, Xueliang, Zhang, Xin, Cheng, Lin, Liu, Yi, Yang, Yang, Fan, Ping, Wang, Qingnan, Lin, Yi, Zhang, Junfeng, Li, Chunlei, Mao, Ying, Wang, Qin, Su, Xiaolan, Zhang, Shuang, Peng, Yong, Yang, Hanshuo, Hu, Xun, Yang, Jinliang, Huang, Meijuan, Xiang, Rong, Yu, Dechao, Zhou, Zongguang, Wei, Yuquan, and Deng, Hongxin

Published
2023
Full Text
View/download PDF

49. CTNI-08. DB102-01 ENGAGE STUDY: A BIOMARKER-GUIDED, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER PHASE 3 CLINICAL TRIAL OF DB102 IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)

Author

Bota, Daniela, Butowski, Nicholas, Piccioni, David, De la Fuente, Macarena, Mao, Ying, Li, Wen-Bin, Trusheim, John, Fink, Karen, Campian, Jian, Lobbous, Mina, Portnow, Jana, Zhu, Jay-Jiguang, Pearlman, Michael, Rudnick, Jeremy, Lesser, Glen, Drappatz, Jan, Vaillant, Brian, Sun, Show-Li, and Luo, Wen

Subjects
Clinical Research, Rare Diseases, Brain Disorders, Brain Cancer, Neurosciences, Clinical Trials and Supportive Activities, Genetics, Cancer, Patient Safety, Orphan Drug, Human Genome, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Good Health and Well Being, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Abstract: Precision medicine is vital for treating many cancers. Lack of valid biomarkers might contribute to the failure of drug therapy for GBM. The Denovo Genomic Marker 1 (DGM1), a novel pharmacogenomic biomarker, has been discovered by a genome-wide screen of patients treated with DB102 (enzastaurin) in a trial for lymphoma. Similarly, retrospective analyses showed that DB102 significantly improved outcomes in the biomarker positive GBM patients treated with DB102, regardless of MGMT promoter methylation status. The ENGAGE Study (DB102-01, NCT03776071) is a global Phase 3 clinical trial to confirm clinical benefits in patients with newly diagnosed GBM who are DGM1 biomarker positive. This is a prospective, randomized, double-blind, placebo-controlled, multi-center study. A total of 318 patients with newly diagnosed GBM will be enrolled. After screening, patients will be randomized to receive radiation therapy (RT) and temozolomide (TMZ) plus either DB102 or a matched placebo for 6 weeks in the Concurrent Phase, followed by DB102 or placebo for approximately 5 weeks in the Single-Agent Phase and then TMZ plus DB102 or placebo in the Adjuvant Phase (up to 12 cycles). Thereafter DB102 or placebo may be continued as a single agent for up to 2 years. The primary endpoint is overall survival (OS). The secondary endpoints include progression free survival (PFS), objective response rate (ORR) and drug safety. By April 2021, the safety-run-in part was completed. The study is now open for enrollment in the US and soon in Canada and China.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results